116 related articles for article (PubMed ID: 23482748)
21. Torin2 Potentiates Anticancer Effects on Adult T-Cell Leukemia/Lymphoma by Inhibiting Mammalian Target of Rapamycin.
Watanabe T; Sato A; Kobayashi-Watanabe N; Sueoka-Aragane N; Kimura S; Sueoka E
Anticancer Res; 2016 Jan; 36(1):95-102. PubMed ID: 26722032
[TBL] [Abstract][Full Text] [Related]
22. Targeted inhibition of mTORC2 prevents osteosarcoma cell migration and promotes apoptosis.
Wang X; Lai P; Zhang Z; Huang M; Wang L; Yin M; Jin D; Zhou R; Bai X
Oncol Rep; 2014 Jul; 32(1):382-8. PubMed ID: 24840134
[TBL] [Abstract][Full Text] [Related]
23. Effects of rapamycin on cell proliferation and phosphorylation of mTOR and p70(S6K) in HepG2 and HepG2 cells overexpressing constitutively active Akt/PKB.
Varma S; Khandelwal RL
Biochim Biophys Acta; 2007 Jan; 1770(1):71-8. PubMed ID: 16952420
[TBL] [Abstract][Full Text] [Related]
24. Combination of mTOR and EGFR kinase inhibitors blocks mTORC1 and mTORC2 kinase activity and suppresses the progression of colorectal carcinoma.
Wang Q; Wei F; Li C; Lv G; Wang G; Liu T; Bellail AC; Hao C
PLoS One; 2013; 8(8):e73175. PubMed ID: 23991179
[TBL] [Abstract][Full Text] [Related]
25. Dual inhibition of the mTORC1 and mTORC2 signaling pathways is a promising therapeutic target for adult T-cell leukemia.
Kawata T; Tada K; Kobayashi M; Sakamoto T; Takiuchi Y; Iwai F; Sakurada M; Hishizawa M; Shirakawa K; Shindo K; Sato H; Takaori-Kondo A
Cancer Sci; 2018 Jan; 109(1):103-111. PubMed ID: 29077243
[TBL] [Abstract][Full Text] [Related]
26. Both mTORC1 and mTORC2 are involved in the regulation of cell adhesion.
Chen L; Xu B; Liu L; Liu C; Luo Y; Chen X; Barzegar M; Chung J; Huang S
Oncotarget; 2015 Mar; 6(9):7136-50. PubMed ID: 25762619
[TBL] [Abstract][Full Text] [Related]
27. The effect of fludrocortisone on the uterine receptivity partially mediated by ERK1/2-mTOR pathway.
Hesam Shariati MB; Seghinsara AM; Shokrzadeh N; Niknafs B
J Cell Physiol; 2019 Nov; 234(11):20098-20110. PubMed ID: 30968418
[TBL] [Abstract][Full Text] [Related]
28. Growth inhibitory effect of rapamycin in Hodgkin-lymphoma cell lines characterized by constitutive NOTCH1 activation.
Nagy N; Hajdu M; Márk Á; Király PA; Tóth M; Dankó T; Csóka M; Sebestyén A
Tumour Biol; 2016 Oct; 37(10):13695-13704. PubMed ID: 27473087
[TBL] [Abstract][Full Text] [Related]
29. Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer.
Li H; Lin J; Wang X; Yao G; Wang L; Zheng H; Yang C; Jia C; Liu A; Bai X
Breast Cancer Res Treat; 2012 Aug; 134(3):1057-66. PubMed ID: 22476852
[TBL] [Abstract][Full Text] [Related]
30. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
Sun SY; Rosenberg LM; Wang X; Zhou Z; Yue P; Fu H; Khuri FR
Cancer Res; 2005 Aug; 65(16):7052-8. PubMed ID: 16103051
[TBL] [Abstract][Full Text] [Related]
31. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.
Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ
J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586
[TBL] [Abstract][Full Text] [Related]
32. An mTORC1/2 kinase inhibitor enhances the cytotoxicity of gemtuzumab ozogamicin by activation of lysosomal function.
Maimaitili Y; Inase A; Miyata Y; Kitao A; Mizutani Y; Kakiuchi S; Shimono Y; Saito Y; Sonoki T; Minami H; Matsuoka H
Leuk Res; 2018 Nov; 74():68-74. PubMed ID: 30300823
[TBL] [Abstract][Full Text] [Related]
33. Acetaldehyde promotes rapamycin-dependent activation of p70(S6K) and glucose uptake despite inhibition of Akt and mTOR in dopaminergic SH-SY5Y human neuroblastoma cells.
Fang CX; Yang X; Sreejayan N; Ren J
Exp Neurol; 2007 Jan; 203(1):196-204. PubMed ID: 16962100
[TBL] [Abstract][Full Text] [Related]
34. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
35. Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways.
Liu L; Li F; Cardelli JA; Martin KA; Blenis J; Huang S
Oncogene; 2006 Nov; 25(53):7029-40. PubMed ID: 16715128
[TBL] [Abstract][Full Text] [Related]
36. mTOR inhibitor PP242 increases antitumor activity of sulforaphane by blocking Akt/mTOR pathway in esophageal squamous cell carcinoma.
Lu Z; Zhang Y; Xu Y; Wei H; Zhao W; Wang P; Li Y; Hou G
Mol Biol Rep; 2022 Jan; 49(1):451-461. PubMed ID: 34731371
[TBL] [Abstract][Full Text] [Related]
37. The immunosuppressant tributyltin oxide blocks the mTOR pathway, like rapamycin, albeit by a different mechanism.
Osman AM; van Loveren H
J Appl Toxicol; 2014 Dec; 34(12):1361-7. PubMed ID: 24375594
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of the mTORC2 and chaperone pathways to treat leukemia.
Zhang F; Lazorchak AS; Liu D; Chen F; Su B
Blood; 2012 Jun; 119(25):6080-8. PubMed ID: 22566604
[TBL] [Abstract][Full Text] [Related]
39. PI3K/mTOR signaling pathways in medulloblastoma.
Mohan AL; Friedman MD; Ormond DR; Tobias M; Murali R; Jhanwar-Uniyal M
Anticancer Res; 2012 Aug; 32(8):3141-6. PubMed ID: 22843885
[TBL] [Abstract][Full Text] [Related]
40. Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin on initiation factor 4E-binding proteins.
Wang X; Beugnet A; Murakami M; Yamanaka S; Proud CG
Mol Cell Biol; 2005 Apr; 25(7):2558-72. PubMed ID: 15767663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]